Skip to main content
. 2020 Apr 29;22(Suppl C):C2–C14. doi: 10.1093/eurheartj/suaa004

Table 1.

Bevacizumab-associated venous and arterial thromboembolic risk: meta-analyses of randomized controlled trials

Meta-analysis Year Patients/number of studies Tumour subtypes VTE risk
VTE
 Scappaticci et al.6 2007 1745/5 mBC, mCRC, NSCLC RR: 0.89, 95% CI: 0.66–1.20; P = 0.44
 Nalluri et al.7 2008 7956/15 mBC, mCRC, NSCLC, RCC, PC, MS

  • RR: 1.33, 95% CI: 1.13–1.56; P = 0.001

  • aRR: 1.10, 95% CI: 0.89–1.36; P = NS
 Hurwitz et al.8 2011 6055/10 mBC, mCRC, NSCLC, RCC, PC, RR: 0.89, 95% CI: 0.66–1.20; P = 0.44
Meta-analysis Year Patients/number of studies Tumour subtypes ATE risk
ATE
 Scappaticci et al.6 2007 1745/5 mBC, mCRC, NSCLC RR: 2.0, 95% CI: 1.05–3.75; P = 0.031
 Ranpura et al.9 2010 12 611/20 Advanced solid tumours RR: 1.44, 95% CI: 1.08–1.91; P = 0.013
 Schutz et al.10 2011 13 026/20 mBC, mCRC, NSCLC, RCC, PC, MS RR: 1.46, 95% CI: 1.11–1.93; P = 0.007

mBC, metastatic breast cancer; mCRC, metastatic colorectal carcinoma; MS, mesothelioma; NS, not significant; NSCLC, non-small-cell lung cancer; PC, pancreatic cancer; RCC, renal cell carcinoma; RR, risk ratio.

a

Exposure-adjusted VTE RR.